Calliditas Therapeutics Partner Everest Medicines Introduces Nefecon in China

Calliditas Therapeutics Partner Everest Medicines Introduces Nefecon in China

By, Admin 16 May 2024

Overview

Calliditas Therapeutics AB announces that its partner Everest Medicines has launched Nefecon in China.

IgA nephropathy: Chinese Epidemiology

  • China, which is estimated to have up to 5 million patients suffering from the progressive autoimmune disease, IgA nephropathy (IgAN), has the highest prevalence of primary glomerular diseases in the world, with IgAN accounting for about 35% to 50% of cases with a biopsy proven incidence of over 100,000 patients per year. 
  • There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian countries.

Words from CEO 

“This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO.

Phase 3 NefIgArd Trial Trial

  • Results from the Chinese subpopulation analysis of the Phase 3 NefIgArd trial, presented at the American Society of Nephrology (ASN) Kidney Week in 2023, provided evidence that the treatment effect of Nefecon in the Chinese cohort was greater than in the global data set with regards to kidney function, proteinuria and microhaematuria. 
  • In the Chinese cohort, the mean absolute change from baseline in estimated glomerular filtration rate (eGFR) at 24 months showed an approximately 66% reduction in loss of kidney function with Nefecon over the period, compared with a 50% reduction in loss of eGFR in the global data set.

Conditional Approval for Nefecon

  • Nefecon was awarded conditional approval in IgAN by China’s National Medical Products Administration (NMPA) in November 2023. 
  • In addition to being approved and commercially launched in Mainland China, Nefecon has also received approval in Macau, Hong Kong and Singapore, and was successfully commercially launched and first prescribed in Macau at the end of last year.  
  • New Drug Applications (NDA) for Nefecon were also successfully accepted for review in Taiwan and South Korea at the end of 2023.

Calliditas Therapeutics

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!